THE LIFELINE WITHIN REACH? THE FIGHT FOR ESSENTIAL MEDICINES IN KENYA (SIOP 2026) - Oct 23, 2026 - Abstract #VIRTUAL-040; "Three modern medicines—rituximab, blinatumomab, and pegaspargase—are used as case studies to illustrate the consequences of exclusion from the national list. The gap between basic and modern cancer care in Kenya is not merely a supply issue but reflects deeper systemic barriers, including slow EML updates, high drug costs, and weak procurement systems. Urgent action is needed: accelerated EML revisions, aggressive price negotiations, and global advocacy for equitable access. Closing this innovation gap is a moral imperative to ensure every child, regardless of birthplace, has a fighting chance at survival."
|